Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK. (Q37871569)

24 August 2017

1 reference

title

Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK. (English)

1 reference

24 August 2017

0 references

3

1 reference

24 August 2017

Luis M Blanco-Colio

1

0 references

Juan A Moreno

object named as

Juan A Moreno

5

0 references

Jose L Martín-Ventura

object named as

Jose L Martín-Ventura

2

0 references

Alberto Ortiz

object named as

Alberto Ortiz

7

0 references

author name string

Mahmut I Yilmaz

4

1 reference

PubMed ID

21538911

24 August 2017

Carmen Gómez-Guerrero

6

1 reference

PubMed ID

21538911

24 August 2017

Jesús Egido

8

1 reference

24 August 2017

28 April 2011

1 reference

Proteomics - Clinical Applications

24 August 2017

1 reference

24 August 2017

5

1 reference

24 August 2017

5-6

1 reference

24 August 2017

281-288

1 reference

Multiple biomarkers for the prediction of first major cardiovascular events and death

24 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Biology of atherosclerotic plaques: what we are learning from proteomic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Candidate-based proteomics in the search for biomarkers of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Cardiovascular proteomics: tools to develop novel biomarkers and potential applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Proteomic strategies in the search of new biomarkers in atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Considering TWEAK as a target for therapy in renal and vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

The clinical implications of endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

21 January 2018

Endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Kidney disease and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Peripheral Artery Disease Is Associated With a High CD163/TWEAK Plasma Ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201000102

21 January 2018

Identifiers

DOI

10.1002/PRCA.201000102

1 reference

24 August 2017

1 reference

PubMed ID

21538911